Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | BMC Medicine

Fig. 2

From: Cancer immunotherapy: the beginning of the end of cancer?

Fig. 2

Genetic T cell engineering for the improvement and broadening of tumor-infiltrating lymphocyte (TIL) therapy. Chimeric antigen receptors (CARs) consist of an Ig variable extracellular domain fused to a T cell receptor (TCR) constant domain. The engineered T cells obtain the antigen-recognition properties of antibodies and thus are targeted against any potential cell surface target antigen. The expression of the TCR confers the engineered T cell with the antigen specificity of the transferred TCR. TIL therapy with TCRs is feasible for patients whose tumor harbors the human leukocyte antigen (HLA) allele and expresses the target antigen recognized by the TCR

Back to article page